Fast-growing cancer could be slowed by common blood pressure drug, research shows
PositiveU.S News
- Researchers have found that hydralazine, an established blood pressure drug, can potentially slow the progression of aggressive brain cancer by targeting cellular oxygen sensors. This unexpected discovery highlights the drug's dual role beyond its original purpose, opening new pathways for cancer treatment.
- The implications of this research are significant, as brain cancer is notoriously difficult to treat, and existing therapies often have limited effectiveness. The ability of hydralazine to impact tumor growth could lead to new treatment protocols and improve patient outcomes.
- This development underscores a growing trend in the medical field where repurposing existing medications is explored as a viable strategy against complex diseases like cancer. The findings may encourage further investigation into other off
— via World Pulse Now AI Editorial System
